A Phase I/II Safety and Tolerability Dose Escalation Study of Autologous Stem Cells to Patients With Liver Insufficiency

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Liver Disease
Interventions
BIOLOGICAL

Autologous Expanded CD34+ Haemopoietic cells

"Autologous expanded CD34+ cells obtained by leukapheresis on a single occasion by infusion into the hepatic artery or portal vein.~Patient numbers 01 and 02 will receive 1x109 cells Patient numbers 03 and 04 will receive 1x1010 cells Patient numbers 05 and 06 will receive 2x1010 cells Patient numbers 07 and 08 will receive 5x1010 cells"

Trial Locations (1)

W12 0HS

Imperial College Healthcare Trust, London

All Listed Sponsors
lead

Imperial College London

OTHER

NCT00655707 - A Phase I/II Safety and Tolerability Dose Escalation Study of Autologous Stem Cells to Patients With Liver Insufficiency | Biotech Hunter | Biotech Hunter